Zenas BioPharma (ZBIO)
Develops obexelimab, a licensed antibody that quiets B-cell activity in immune diseases without depleting the cells.
$32.44
Pre-market−0.65 (−1.98%)
At close$33.09(+3.47%)
Something off on this page? Send us feedback.
Next report
Nov 12, 2026
estimated · in 70 days
EPS estimate
−$1.22
Revenue estimate
$1.0M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported−$0.80−$1.25−$1.22−$1.10−$1.46−$1.77−$1.77Pending
Estimate−$1.11−$1.02−$0.87−$1.00−$1.37−$1.12−$1.12−$1.22
Surprise+27.9%−22.5%−40.2%−9.8%−6.6%−58.0%−58.0%—
RevenueReportedEstimate
May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported$10.0M————$1.0M$1.0MPending
Estimate$1.3M$3.8M$28.8M$13.3M$25.0M$15.0M$15.0M$1.0M
Surprise+700.0%————−93.3%−93.3%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$1.22 | — | — |
| Aug 2026 | −$1.12 | −$1.77 | −58.0% |
| Aug 2026 | −$1.12 | −$1.77 | −58.0% |
| May 2026 | −$1.37 | −$1.46 | −6.6% |
| Mar 2026 | −$1.00 | −$1.10 | −9.8% |
The latest year is open to everyone — the 12 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Jun 2024 | |||
| Mar 2024 | |||
| Dec 2023 | |||
| Sep 2023 | |||
| Jun 2023 | |||
| Mar 2023 | |||
| Dec 2022 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | −$1.22 | — | — | $1.0M | — | — | — |
| Aug 13, 2026 | −$1.12 | −$1.77 | −58.0% | $15.0M | $1.0M | −93.3% | −6.7% |
| Aug 12, 2026 | −$1.12 | −$1.77 | −58.0% | $15.0M | $1.0M | −93.3% | −3.5% |
| May 13, 2026 | −$1.37 | −$1.46 | −6.6% | $25.0M | — | — | −5.2% |
| Mar 16, 2026 | −$1.00 | −$1.10 | −9.8% | $13.3M | — | — | +1.1% |
The latest year is open to everyone — the 12 quarters behind it read with an account. Sign in | |||||||
| Nov 12, 2025 | |||||||
| Aug 12, 2025 | |||||||
| May 15, 2025 | |||||||
| Mar 25, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Jun 30, 2024 | |||||||
| Mar 31, 2024 | |||||||
| Dec 31, 2023 | |||||||
| Sep 30, 2023 | |||||||
| Jun 30, 2023 | |||||||
| Mar 31, 2023 | |||||||
| Dec 31, 2022 | |||||||